The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Open accessAbstract
Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why inhibition of these ubiquitous regulators should have gene-specific effects in tumor cells. Here, we investigate how inhibition of the widely expressed transcriptional coactivator BRD4 leads to selective inhibition of the MYC oncogene in multiple myeloma (MM). BRD4 and Mediator were found to co-occupy thousands of enhancers associated with active genes. They also co-occupied a small set of exceptionally large super-enhancers associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impacted genes with super-enhancers, including MYC. Super-enhancers were found at key oncogenic drivers in many other tumor cells. These observations have implications for the discovery of cancer therapeutics directed at components of super-enhancers in diverse tumor types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SEs in both HCC and TAN were associated with GO terms related to metabolic genes (e.g. CYP3A4, SLC38A4, and IGFBP1) (Fig. 2c)20,21,58.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829
Pruitt, K. D., Tatusova, T. A., & Maglott, D. R. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl842 · Cited by 4,441
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
Self-citationSelective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citationMaster Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Self-citationThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,767
Cabili, M. N., Trapnell, C., Goff, L. A., Koziol, M. J., Tazón‐Vega, B., Regev, A., & Rinn, J. L. (2011) · Genes & Development · doi:10.1101/gad.17446611 · Cited by 3,551
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,008
Narita, T., Ito, S., Higashijima, Y., Chu, W. K., Neumann, K., Walter, J., Satpathy, S., Liebner, T., Hamilton, W. B., Maskey, E., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.008 · Cited by 228
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
Fu, L., Tian, M., Li, X., Li, J., Huang, J. M., Ouyang, L., Zhang, Y., & Liu, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3551 · Cited by 231
Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Wang, Z., Zhang, Z.-C., Wu, Y., Pi, Y., Lou, S., Liu, T., Lou, G., & Yang, C. Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01647-6 · Cited by 251
Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis
Savitski, M. M., Zinn, N., Faelth-Savitski, M., Poeckel, D., Gade, S., Becher, I., Muelbaier, M., Wagner, A. J., Strohmer, K., Werner, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.030 · Cited by 217
Chromatin signatures of cancerPreprint
Morgan, M. A., & Shilatifard, A. (2015) · Genes & Development · doi:10.1101/gad.255182.114 · Cited by 218
Di Micco, R., Fontanals-Cirera, B., Low, V., Ntziachristos, P., Yuen, S. K., Lovell, C. D., Dolgalev, I., Yonekubo, Y., Zhang, G., Rusinova, E., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.055 · Cited by 217
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Brien, G. L., Remillard, D., Shi, J., Hemming, M. L., Chabon, J., Wynne, K. J., Dillon, E., Cagney, G., van Mierlo, G., Baltissen, M. P. A., et al. (2018) · eLife · doi:10.7554/elife.41305 · Cited by 222
Self-citationTherapeutic targeting of ependymoma as informed by oncogenic enhancer profiling
Mack, S. C., Pajtler, K. W., Chávez, L., Okonechnikov, K., Bertrand, K. C., Wang, X., Erkek, S., Alexander Joel Federation, Song, A., Lee, C., et al. (2017) · Nature · doi:10.1038/nature25169 · Cited by 217
Self-citationBhadury, J., Nilsson, L. M., Muralidharan, S. V., Green, L. C., Li, Z., Gesner, E. M., Hansen, H. C., Keller, U. B., McLure, K. G., & Nilsson, J. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406722111 · Cited by 221
Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma
Jiang, Y.-Y., Lin, D., Mayakonda, A., Hazawa, M., Ding, L., Chien, W.-W., Xu, L., Chen, Y., Xiao, J., Senapedis, W. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-311818 · Cited by 214
Pastori, C., Kapranov, P., Penas, C., Peschansky, V. J., Volmar, C., Sarkaria, J. N., Bregy, A., Komotar, R. J., Laurent, G. S., Ayad, N. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424220112 · Cited by 218
Enhancer Activation Requires trans-Recruitment of a Mega Transcription Factor Complex
Liu, Z., Merkurjev, D., Yang, F., Li, W., Oh, S., Friedman, M. J., Song, X., Zhang, F., Ma, Q., Ohgi, K. A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.027 · Cited by 221
The Overlooked Fact: Fundamental Need for Spike-In Control for Virtually All Genome-Wide Analyses
Chen, K., Hu, Z., Xia, Z., Zhao, D., Li, W., & Tyler, J. K. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00970-14 · Cited by 212
NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment
French, C. A. (2018) · Pathology International · doi:10.1111/pin.12727 · Cited by 215
Catarino, R. R., & Stark, A. (2018) · Genes & Development · doi:10.1101/gad.310367.117 · Cited by 215
Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer
Heyn, H., Vidal, E., Ferreira, H. J., Vizoso, M., Sayols, S., Gómez, A., Morán, S., Boqué-Sastre, R., Guil, S., Martínez‐Cardús, A., et al. (2016) · Genome biology · doi:10.1186/s13059-016-0879-2 · Cited by 211
Self-citationHaller, F., Bieg, M., Will, R. D., Körner, C., Weichenhan, D., Bott, A., Ishaque, N., Lutsik, P., Moskalev, E. A., Mueller, S. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08069-x · Cited by 209
SEdb: a comprehensive human super-enhancer database
Jiang, Y., Qian, F., Bai, X., Liu, Y., Wang, Q., Ai, B., Han, X., Shi, S., Zhang, J., Li, X., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1025 · Cited by 209
CDK9: a signaling hub for transcriptional control
Bacon, C. W., & D’Orso, I. (2018) · Transcription · doi:10.1080/21541264.2018.1523668 · Cited by 206
Landscape of cohesin-mediated chromatin loops in the human genome
Grubert, F., Srivas, R., Spacek, D. V., Kasowski, M. M., Ruiz-Velasco, M., Sinnott-Armstrong, N., Greenside, P., Narasimha, A. M., Liu, Q., Geller, B. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2151-x · Cited by 203
Shu, S., Wu, H., Ge, J. Y., Zeid, R., Harris, I. S., Jovanović, B., Murphy, K. C., Wang, B., Qiu, X., Endress, J. E., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.027 · Cited by 204
Self-citationLee, J., Park, Y.-K., Park, S., Jang, Y., Waring, N. A., Dey, A., Ozato, K., Lai, B., Peng, W., & Ge, K. (2017) · Nature Communications · doi:10.1038/s41467-017-02403-5 · Cited by 209
Rev-erbα Dynamically Modulates Chromatin Looping to Control Circadian Gene Transcription
Kim, Y. H., Marhon, S. A., Zhang, Y.-X., Steger, D. J., Won, K.-J., & Lazar, M. (2018) · Science · doi:10.1126/science.aao6891 · Cited by 195
The Chemical Biology of Reversible Lysine Post-translational Modifications
Wang, Z. A., & Cole, P. A. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.002 · Cited by 216
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaPreprint
Huang, C., Lujambio, A., Zuber, J. A., Tschaharganeh, D. F., Doran, M. G., Evans, M. J., Kitzing, T. M., Zhu, N., de Stanchina, E., Sawyers, C. L., et al. (2014) · Genes & Development · doi:10.1101/gad.244368.114 · Cited by 204
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
Kurimchak, A., Shelton, C., Duncan, K., Johnson, K. J., Brown, J., O’Brien, S. W., Gabbasov, R. T., Fink, L. S., Li, Y., Lounsbury, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.091 · Cited by 204
PRC2.1 and PRC2.2 Synergize to Coordinate H3K27 Trimethylation
Healy, E., Mucha, M., Glancy, E., Fitzpatrick, D. J., Conway, E., Neikes, H. K., Monger, C., van Mierlo, G., Baltissen, M. P. A., Koseki, Y., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.012 · Cited by 213
Alekseyenko, A. A., Walsh, E. M., Wang, X., Grayson, A. R., Hsi, P. T., Kharchenko, P. V., Kuroda, M. I., & French, C. A. (2015) · Genes & Development · doi:10.1101/gad.267583.115 · Cited by 205
An epigenomic approach to therapy for tamoxifen-resistant breast cancer
Feng, Q. F., Zhang, Z., Shea, M. J., Creighton, C. J., Coarfa, C., Hilsenbeck, S. G., Lanz, R. B., He, B., Wang, L., Fu, X., et al. (2014) · Cell Research · doi:10.1038/cr.2014.71 · Cited by 195
Self-citationThe reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia
Beekman, R., Chapaprieta, V., Russiñol, N., Vilarrasa‐Blasi, R., Verdaguer-Dot, N., Martens, J. H. A., Duran‐Ferrer, M., Kulis, M., Serra, F., Javierre, B. M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0028-4 · Cited by 196
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling
Liu, F., Hon, G. C., Villa, G. R., Turner, K. M., Ikegami, S., Yang, H., Ye, Z., Li, B., Kuan, S., Lee, A. Y., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.002 · Cited by 194
Moorthy, S. D., Davidson, S., Shchuka, V. M., Singh, G., Malek-Gilani, N., Langroudi, L., Martchenko, A., So, V., Macpherson, N. N., & Mitchell, J. A. (2016) · Genome Research · doi:10.1101/gr.210930.116 · Cited by 202
Histone H3 lysine 4 monomethylation modulates long-range chromatin interactions at enhancers
Yan, J., Chen, S.-A. A., Local, A., Liu, T., Qiu, Y., Lee, A. Y., Jung, I., Preißl, S., Rivera, C. M., Wang, C., et al. (2018) · Cell Research · doi:10.1038/cr.2018.1 · Cited by 198
Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180
Fiskus, W. C., Sharma, S., Qi, J., Valenta, J. A., Schaub, L. J., Shah, B., Peth, K., Portier, B. P., Rodríguez, M., Devaraj, S. G. T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0770 · Cited by 195
Self-citationLai, B., Lee, J.-E., Jang, Y., Wang, L., Peng, W., & Ge, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx234 · Cited by 191
Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation
Stratton, M. S., Bagchi, R. A., Felisbino, M. B., Hirsch, R. A., Smith, H. E., Riching, A. S., Enyart, B. Y., Koch, K. A., Cavasin, M. A., Alexanian, M., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315125 · Cited by 179
Self-citationTargeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Henssen, A. G., Althoff, K., Odersky, A., Beckers, A., Koche, R. P., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1449 · Cited by 190
Saenz, D. T., Fiskus, W. C., Qian, Y., Manshouri, T., Rajapakshe, K., Raina, K., Coleman, K. G., Crew, A. P. A., Shen, A., Mill, C. P., et al. (2017) · Leukemia · doi:10.1038/leu.2016.393 · Cited by 187
Ceribelli, M., Kelly, P. N., Shaffer, A. L., Wright, G. W., Xiao, W., Yang, Y., Griner, L. A. M., Guha, R., Shinn, P., Keller, J. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411701111 · Cited by 187
Nagaraja, S., Quezada, M. A., Gillespie, S. M., Arzt, M., Lennon, J., Woo, P. J., Hovestadt, V., Kambhampati, M., Filbin, M. G., Suvà, M. L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.030 · Cited by 190
Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex
Shen, H., Xu, W., Guo, R., Rong, B., Gu, L., Wang, Z., He, C., Zheng, L., Hu, X., Hu, Z., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.064 · Cited by 184
MYC—Master Regulator of the Cancer Epigenome and Transcriptome
Poole, C. J., & van Riggelen, J. (2017) · Genes · doi:10.3390/genes8050142 · Cited by 180
Nagarajan, S., Hossan, T., Alawi, M., Najafova, Z., Indenbirken, D., Bedi, U., Taipaleenmäki, H., Batalla, I. B., Scheller, M., Loges, S., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.016 · Cited by 189
Gimple, R. C., Kidwell, R. L., Kim, L. J. Y., Sun, T., Gromovsky, A. D., Wu, Q., Wolf, M. E., Lv, D., Bhargava, S., Jiang, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0061 · Cited by 182
Targeting Cancer Cells with BET Bromodomain InhibitorsPreprint
Xu, Y., & Vakoc, C. R. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026674 · Cited by 187
Self-citationWalker, B. A., Wardell, C. P., Brioli, A., Boyle, E. M., Kaiser, M., Begum, D. B., Dahir, N. B., Johnson, D. C., Ross, F. M., Davies, F. E., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.13 · Cited by 182
Bunn, P. A., Minna, J. D., Augustyn, A., Gazdar, A. F., Ouadah, Y., Krasnow, M. A., Berns, A. J. M., Brambilla, E. M., Rekhtman, N., Massion, P. P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.012 · Cited by 180
Enhancers in disease: molecular basis and emerging treatment strategies
Claringbould, A., & Zaugg, J. B. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.07.012 · Cited by 179
Sun, B., Fiskus, W. C., Qian, Y., Rajapakshe, K., Raina, K., Coleman, K. G., Crew, A. P. A., Shen, A., Saenz, D. T., Mill, C. P., et al. (2017) · Leukemia · doi:10.1038/leu.2017.207 · Cited by 185
Genome-wide localization of small molecules
Anders, L., Guenther, M. G., Qi, J., Fan, Z. P., Marineau, J., Rahl, P. B., Lovén, J., Sigova, A. A., Smith, W. B., Lee, T. I., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2776 · Cited by 182
Self-citationPotent BRD4 inhibitor suppresses cancer cell-macrophage interaction
Yin, M., Guo, Y., Hu, R., Cai, W. L., Li, Y., Pei, S., Sun, H., Peng, C., Li, J., Ye, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15290-0 · Cited by 179
Jiang, Y., Jiang, Y., Li, C.-Q., Zhang, Y., Dakle, P., Hp, K., Deng, J.-W., Lin, R. Y., Yan, Y., Xie, J.-J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.050 · Cited by 186
Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions
Brand, M. J. D., Measures, A. M., Wilson, B. G., Cortopassi, W. A., Alexander, R. P., Höss, M., Hewings, D. S., Rooney, T. P. C., Paton, R. S., & Conway, S. J. (2014) · ACS Chemical Biology · doi:10.1021/cb500996u · Cited by 177
Thiecke, M. J., Wutz, G., Muhar, M., Tang, W., Bevan, S., Malysheva, V., Stocsits, R., Neumann, T., Zuber, J., Fraser, P., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107929 · Cited by 177
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Inoue‐Yamauchi, A., Jeng, P., Kim, K., Chen, H., Han, S., Ganesan, Y. T., Ishizawa, K., Jebiwott, S., Dong, Y., Pietanza, M. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms16078 · Cited by 180
Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
Lambert, J., Picaud, S., Fujisawa, T., Hou, H., Savitsky, P. A., Uusküla-Reimand, L., Gupta, G. D., Abdouni, H. S., Lin, Z., Tucholska, M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.11.006 · Cited by 183
Dawson, M. A., Gudgin, E. J., Horton, S. J., Giotopoulos, G., Meduri, E., Robson, S. C., Cannizzaro, E., Osaki, H., Wiese, M., Putwain, S., et al. (2013) · Leukemia · doi:10.1038/leu.2013.338 · Cited by 176
Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery
Greer, C. B., Tanaka, Y., Kim, Y. J., Xie, P., Zhang, M. Q., Park, I.-H., & Kim, T. H. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.013 · Cited by 174
AP-1 activity induced by co-stimulation is required for chromatin opening during T cell activation
Yukawa, M., Jagannathan, S., Vallabh, S., Kartashov, A. V., Chen, X., Weirauch, M. T., & Barski, A. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182009 · Cited by 173
Systematic identification of silencers in human cells
Pang, B., & Snyder, M. P. (2020) · Nature Genetics · doi:10.1038/s41588-020-0578-5 · Cited by 183
Epstein-Barr Virus Oncoprotein Super-enhancers Control B Cell Growth
Zhou, H., Schmidt, S. C. S., Jiang, S., Willox, B., Bernhardt, K., Liang, J., Johannsen, E., Kharchenko, P. V., Gewurz, B. E., Kieff, E. D., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2014.12.013 · Cited by 174
Current and Future Treatment Strategies for Rhabdomyosarcoma
Chen, C. Y., García, H. D., Scheer, M., & Henssen, A. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01458 · Cited by 180
Divergent Transcription: A Driving Force for New Gene Origination?
Wu, X., & Sharp, P. A. (2013) · Cell · doi:10.1016/j.cell.2013.10.048 · Cited by 180
Rewiring cancer drivers to activate apoptosis
Gourisankar, S. P., Krokhotin, A., Ji, W., Liu, X., Chang, C.-Y., Kim, S. H., Li, Z., Wenderski, W., Simanauskaite, J., Yang, H., et al. (2023) · Nature · doi:10.1038/s41586-023-06348-2 · Cited by 174
Camicia, R., Winkler, H. C., & Hassa, P. O. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0474-2 · Cited by 177
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Cato, L., de Tribolet-Hardy, J., Lee, I. I., Rottenberg, J. T., Coleman, I. M., Melchers, D., Houtman, R., Xiao, T., Li, W., Uo, T., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.008 · Cited by 171
Spatiotemporal DNA methylome dynamics of the developing mouse fetus
He, Y., Hariharan, M., Gorkin, D. U., Dickel, D. E., Luo, C., Castanon, R., Nery, J. R., Lee, A. Y., Zhao, Y., Huang, H., et al. (2020) · Nature · doi:10.1038/s41586-020-2119-x · Cited by 165
A compendium and comparative epigenomics analysis of cis-regulatory elements in the pig genome
Zhao, Y., Hou, Y., Xu, Y., Luan, Y., Zhou, H., Qi, X., Hu, M., Wang, D., Wang, Z., Fu, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22448-x · Cited by 169
Targeting BET Bromodomains for Cancer Treatment
Jung, M., Gelato, K. A., Fernández‐Montalván, A. E., Siegel, S., & Haendler, B. (2015) · Epigenomics · doi:10.2217/epi.14.91 · Cited by 167
Enhancer Malfunction in Cancer
Herz, H., Hu, D., & Shilatifard, A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.02.033 · Cited by 170
Baratta, M. G., Schinzel, A. C., Zwang, Y., Bandopadhayay, P., Bowman-Colin, C., Kutt, J., Curtis, J. D., Piao, H., Wong, L. C., Kung, A. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422165112 · Cited by 171
Self-citationVHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
Yao, X., Tan, J. Y., Lim, K. J., Koh, J., Ooi, W. F., Li, Z., Huang, D., Xing, M., Chan, Y. S., Qu, J. Z., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0375 · Cited by 171
Fu, X., Pereira, R., Angelis, C. D., Veeraraghavan, J., Nanda, S., Qin, L., Cataldo, M. L., Sethunath, V., Mehravaran, S., Gutiérrez, C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911584116 · Cited by 167
Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia
Yashiro–Ohtani, Y., Wang, H., Zang, C., Arnett, K. L., Bailis, W., Ho, Y., Knoechel, B., Lanauze, C. B., Louis, L., Forsyth, K. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407079111 · Cited by 166
Chaidos, A., Caputo, V. S., & Karadimitris, A. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715576662 · Cited by 174
Acute BAF perturbation causes immediate changes in chromatin accessibility
Schick, S., Grosche, S., Kohl, K. E., Drpic, D., Jaeger, M. G., Marella, N., Imrichová, H., Lin, J.-M. G., Hofstätter, G., Schuster, M. K., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00777-3 · Cited by 166
Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies
Yang, H., Kurtenbach, S., Guo, Y., Lohse, I., Durante, M. A., Li, J., Li, Z., Al‐Ali, H., Li, L., Chen, Z., et al. (2017) · Blood · doi:10.1182/blood-2017-06-789669 · Cited by 170
Targeting transcription cycles in cancer
Vervoort, S. J., Devlin, J. R., Kwiatkowski, N. P., Teng, M., Gray, N. S., & Johnstone, R. W. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00411-8 · Cited by 170
Histone Acetyltransferase p300 Induces De Novo Super-Enhancers to Drive Cellular Senescence
Sen, P., Lan, Y., Li, C. Y., Sidoli, S., Donahue, G., Dou, Z., Frederick, B., Chen, Q., Luense, L. J., Garcia, B. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.01.021 · Cited by 164
Thandapani, P. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.014 · Cited by 167
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 184
MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer
Sze, C. C., & Shilatifard, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026427 · Cited by 164
A qPCR ScoreCard quantifies the differentiation potential of human pluripotent stem cells
Tsankov, A. M., Akopian, V., Pop, R., Chetty, S., Gifford, C. A., Daheron, L. M., Tsankova, N. M., & Meissner, A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3387 · Cited by 163
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Rhyasen, G. W., Hattersley, M. M., Yao, Y., Dulak, A. M., Wang, W., Petteruti, P., Dale, I. L., Boiko, S., Cheung, T., Zhang, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0141 · Cited by 166
Ceribelli, M., Hou, E. Z., Kelly, P. N., Huang, D. W., Wright, G. W., Ganapathi, K. A., Evbuomwan, M. O., Pittaluga, S., Shaffer, A. L., Marcucci, G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.002 · Cited by 164
Molecular diversification of regulatory T cells in nonlymphoid tissues
DiSpirito, J. R., Zemmour, D., Ramanan, D., Cho, J., Žilionis, R., Klein, A. M., Benoist, C. O., & Mathis, D. J. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat5861 · Cited by 165
Small-molecule targeting of brachyury transcription factor addiction in chordoma
Sharifnia, T., Wawer, M. J., Chen, T., Huang, Q., Weir, B. A., Sizemore, A. E., Lawlor, M. A., Goodale, A. B., Cowley, G. S., Vázquez, F., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0312-3 · Cited by 159
Self-citationRegulation ofMYCgene expression by aberrant Wnt/β-catenin signaling in colorectal cancer
Rennoll, S. A. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.290 · Cited by 174
A concerted neuron–astrocyte program declines in ageing and schizophrenia
Ling, E., Nemesh, J. C., Goldman, M., Kamitaki, N., Reed, N. M., Handsaker, R. E., Genovese, G., Vogelgsang, J. S., Gerges, S., Kashin, S., et al. (2024) · Nature · doi:10.1038/s41586-024-07109-5 · Cited by 170
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence
Morrow, J. J., Bayles, I., Funnell, A. P. W., Miller, T. E., Saiakhova, A., Lizardo, M. M., Bartels, C. F., Kapteijn, M. Y., Hung, S., Mendoza, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4475 · Cited by 161
Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities
Pierre, R. S., & Kadoch, C. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.02.004 · Cited by 165
Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis
Viny, A. D., Ott, C. J., Spitzer, B. G., Rivas, M. A., Meydan, C., Papalexi, E., Yelin, D., SHANK, K. R., Reyes, J. M., Chiu, A., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20151317 · Cited by 159
Self-citationBET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements
Bhagwat, A. S., Roe, J., Mok, B. Y., Hohmann, A. F., Shi, J., & Vakoc, C. R. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.054 · Cited by 169
Self-citationMYC protein stability is negatively regulated by BRD4
Devaiah, B. N., Mu, J., Akman, B., Uppal, S., Weissman, J. D., Cheng, D., Baranello, L., Nie, Z., Levens, D., & Singer, D. S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919507117 · Cited by 159
Factor, D. C., Corradin, O., Zentner, G. E., Saiakhova, A., Song, L., Chenoweth, J. G., McKay, R. D. G., Crawford, G. E., Scacheri, P. C., & Tesar, P. J. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.05.005 · Cited by 159
Jung, M., Philpott, M., Müller, S., Schulze, J., Badock, V., Eberspächer, U., Moosmayer, D., Bader, B., Schmees, N., Fernández‐Montalván, A. E., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.523019 · Cited by 164
Asangani, I. A., Wilder-Romans, K., Dommeti, V. L., Krishnamurthy, P. M., Apel, I. J., Escara-Wilke, J. F., Plymate, S. R., Navone, N. M., Wang, S., Feng, F. Y.-C., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0472 · Cited by 162
BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer
Hajmirza, A., Emadali, A., Gauthier, A., Casasnovas, O., Gressin, R., & Callanan, M. B. (2018) · Biomedicines · doi:10.3390/biomedicines6010016 · Cited by 162
High-throughput and quantitative assessment of enhancer activity in mammals by CapStarr-seq
Vanhille, L., Griffon, A., Maqbool, M. A., Zacarias-Cabeza, J., Dao, L. T. M., Fernandez, N., Ballester, B., Andrau, J. C., & Spicuglia, S. (2015) · Nature Communications · doi:10.1038/ncomms7905 · Cited by 158
Metadata
- Authors
- Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A.
- Affiliations
- Whitehead Institute for Biomedical Research (US)
- Dana-Farber Cancer Institute (US)
- Cold Spring Harbor Laboratory (US)
- Harvard University (US)
- Corresponding author
- Young, Richard A.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 153
- Issue
- 2
- Pages
- 320-334
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC3760967
- OpenAlex
- W1523117612
- Cited by
- 2,961
- References
- 86
- Citations by year
- 2026: 140 · 2025: 214 · 2024: 261 · 2023: 254 · 2022: 271 · 2021: 327 · 2020: 263 · 2019: 248 · 2018: 218 · 2017: 205 · 2016: 184 · 2015: 175 · 2014: 143 · 2013: 53
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health (5p30ca045508-35)
- National Human Genome Research Institute (HG002668, R01HG002668)
- National Cancer Institute (CA146445, R01CA146445, P30-CA045508, CA45508, P30CA014051)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- super-enhancers, BRD4, MYC oncogene, multiple myeloma, BET inhibitors, JQ1, Mediator complex, transcriptional coactivator, transcription elongation, chromatin regulators, cancer therapy, enhancer disruption
- MeSH terms
- Bromodomain Containing Proteins, Antineoplastic Agents, Azepines, Chromatin, Enhancer Elements, Genetic, Humans, Multiple Myeloma, Neoplasms, Nuclear Proteins, Transcription Factors, Transcription, Genetic, Triazoles, Gene Expression Regulation, Neoplastic, Cell Cycle Proteins, Cell Line, Tumor, Genome-Wide Association Study, Mediator Complex, Transcription Elongation, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
